AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

OptimizeRx Corp Director's Dealing 2022

Aug 19, 2022

33090_dirs_2022-08-19_405f2644-6433-4ec5-b10f-27952502e020.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2022-08-16

Reporting Person: Vos Ellen O'Connor (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	33390	Direct

Footnotes

F1: This amendment is being filed to correct the amount of securities beneficially owned following reported transaction which were understated by 32,890 shares.